Gemifloxacin: A new fluoroquinolone

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 5, 2004, Pages 1117-1152

  Blondeau, Joseph M ^a   Missaghi, Bayan ^b  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b NONE

Author keywords

Fluoroquinolone; Respiratory infections; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEPHALOSPORIN; CHLOROQUINE; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; COTRIMOXAZOLE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ENOXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MACROLIDE; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SUCRALFATE; TELITHROMYCIN; TETRACYCLINE; TROVAFLOXACIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ADULT; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BORDETELLA PERTUSSIS; CHLAMYDIA; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DNA REPLICATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; DYSPEPSIA; ENTEROBACTERIACEAE; ENZYME SYNTHESIS; ERADICATION THERAPY; ESCHERICHIA COLI; FATIGUE; FEMALE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GENUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HEADACHE; HELICOBACTER PYLORI; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; INSOMNIA; LEGIONELLA; LIVER DYSFUNCTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; MYALGIA; MYCOPLASMA; NAUSEA AND VOMITING; NONHUMAN; PROVIDENCIA STUARTII; PSEUDOMONAS; RESPIRATORY TRACT INFECTION; RHINITIS; SINUSITIS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TIME; UREAPLASMA;

ANIMALS; COMMUNITY-ACQUIRED INFECTIONS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; GUINEA PIGS; HUMANS; INTESTINES; MALE; MICROBIAL SENSITIVITY TESTS; MULTICENTER STUDIES; MUTATION; NAPHTHYRIDINES; RABBITS; RANDOMIZED CONTROLLED TRIALS;

EID: 2542560648     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.5.1117     Document Type: Article

References (120)

1. BLONDEAU JM, HANSEN G, BORSOS S, IRVINE L, BLANCO L: In vitro susceptibility of 4903 bacterial isolates of gemifloxcin - an advanced fluoroquinolone. Int. J. Antimicrob. Agents (2003) 9:44-49.
2. HANSEN G, METZLER KL, DRLICA K, BLONDEAU JM: Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2003) 47:440-441.
3. WISE R: Introduction. J. Antimicrob. Chemother. (2000) 46:1-2.
4. BALL P: Quinolone generations: natural history or natural selection? J. Antimicrob. Chemother. (2000) 46:17-24.
5. DOMAGALA J: Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother (1994) 33:685-706.
6. GARCIA I, PASCUAL A, BALLESTA S, JOYANES P, PEREA EJ: Intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. (2000) 44:3193-3195.
7. FUCHS PC, BARRY AL, BROWN SD: In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers and assessment of disk diffusion test interpretive criteria. Diagn. Microbiol. Infect. Dis. (2000) 38:243-253.
8. MCCLOSKEY L MOORE T NICONOVICH N et al.: In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J. Antimicrob. Chemother. (2000) 45:13-21.
9. KING A, MAY J, FRENCH G, PHILLIPS I: Comparative in vitro activity of gemifloxacin. J. Antimicrob. Chemother. (2000) 45:1-12.
10. HAMMERSCHLAG MR: Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review. J. Antimicrob. Chemother. (2000) 45:35-39.
11. DUFFY LB, CRABB D, SEARCEY K et al.: Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma species. J. Antimicrob. Chemother. (2000) 43:29-33.
12. DUBOIS J, SAINT-PIERRE C: Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp. J. Antimicrob. Chemother. (2000) 45:41-46.
13. MINEHART HW, CHALKER AF: In vitro activity of gemifloxacin against Helicobacter pylori. J. Antimicrob. Chemother. (2001) 47:357-368.
14. MORTENSEN JE, RODGERS GL: In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis. J. Antimicrob. Chemother. (2000) 45:47-49.
15. MORRISSEY I, GEORGE JT. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae. J. Antimicrob. Chemother. (2000) 45:107-110.
16. WAITES KB, CRABB DM, DUFFY LB: Inhibitory and bactericidal activities of gemifloxacin and other antimicrobial against Mycoplasma pneumoniae. Int. J. Antimicrob. Agents (2003) 21:574-577.
17. HIGGINS PG, COLEMAN K, AMYES SGB: Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro. J. Antimicrob. Chemother. (2000) 45(Suppl. 1):71-77.
18. MOORE T, KERSHNER K, DONALD B et al.: Post-antibiotic effect (PAE) of gemifloxacin (SP-265805) and ciprofloxacin against Gram-positive and Gram-negative organisms. Paper presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA (1999).
19. MACKENZIE H, FORWARD K, DE AZAVEDO J et al.: Post-antibiotic effect (PAE) of gemifloxacin (SB-265805) in S. pneumoniae with diminished susceptibility to ciprofloxacin. Paper presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA (1999).
20. ALLEN A, BYGATE E, FAESSEL H, ISAAC L, LEWIS A: The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. Inte. J. Antimicrob. Agents (2000) 15:283-289.
21. ALLEN A, BYGATE E, OLIVER S, JOHNSON M, WARD C, CHEON A-J, CHOO YS, KIM IC: Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob. Agents Chemother. (2000) 44:1604-1608.
22. SEO SM, LEE SH, CHOI YJ et al.: Pharmacokinetics of LB20304, a new fluoroquinolone in rats and dogs. Arch. Pharm. Res. (1996) 19:359-367.
23. FORREST A, NIX DL, BALLOW CH, GOSS TF, BIRMINGHAM MC, SCHENTAG JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. (1993) 37:1073-1081.
24. BLONDEAU JM, DRLICA K, HANSEN G, ZHAO X: The relationship between the mutant prevention concentration (MPC) of fluoroquinolones (FQ) against Streptococcus pneumoniae (SP) and the 24-hour dose-response curves. Paper presented at the 7th International Symposium of New Quinolones, Edinburgh, Scotland, UK (2001).
25. HOBAN DJ, BOUCHILLON SK, JOHNSON JL et al.: Gemifloxacin Surveillance Study Research Group: Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Diagn. Microbiol. Infect. Dis. (2001) 40:51-57.
26. ALLEN A BYGATE E VOUSDEN M et al.: Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Antimicrob. Agents Chemother. (2001) 45:540-545.
27. GEE T, ANDREWS JM, ASHBY JP, MARSHALL G, WISE R: Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. J. Chemother. (2001) 47:431-434.
28. DAVY M, BIRD N, ROST KL, FUDER H: Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. Chemotherapy (1999) 45:491-495.
29. VOUSDEN M, ALLEN A, LEWIS A et al.: Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers. Chemotherapy Basel (1999) 45:485-490.
30. DAVY M, ALLEN A, BIRD N, ROST KL, FUDER H: Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. Chemotherapy (1999) 45:478-484.
31. BERRY V, PAGE R, SATTERFIELD J, SINGLEY C, STRAUB R, WOODNUTT G: Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. J. Antimicrob. Chemother. (2000) 45:79-85.
32. BERRY V, PAGE R, SATTERFIELD J, SINGLEY C, STRAUB R, WOODNUTT G: Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection. J. Antimicrob. Chemother. (2000) 45:87-93.
33. EDELSTEIN PH, SHINZATO T, DOYLE E, EDELSTEIN MA: In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. (2001) 45:2204-2209.
34. COTTAGNOUD P, ACOSTA F, COTTAGNOUD M, TAUBER MG: Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumococci in experimental meningitis. Antimicrob. Agents Chemother. (2002) 46:1607-1609.
35. SMIRNOV A, WELLMER A, GERBER J, MAIER K, HENNE S, NAU R: Gemifloxacin is effective in experimental pneumococcal meningitis. Antimicrob. Agents Chemother. (2000) 44:767-770.
36. BARKER PJ, SHEEHAN R, TEILLOL-FOO M et al.: Effect of gemifloxacin on the normal human intestinal microflora. Paper presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA (1999).
37. GARCIA-CALVO G, MOLLEJA A, GIMENEZ MJ et al.: Effects of single oral doses of gemifloxacin (320 milligrams) versus trovafloxacin (200 milligrams) on fecal flora ini healthy volunteers. Antimicrob. Agents Chemother. (2001) 45:608-611.
38. RITTENHAUSE S, DONALD B, NICONOVICH N et al.: Effect of gemifloxacin and comparator quinolones on the development of in vitro bacterial resistance. Paper presented at the 21st International Congress of Chemotherapy, Birmingham, UK (1999).
39. DONG Y, ZHAO X, DOMAGALA J, DRLICA K: Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. (1999) 43:1756-1758.
40. DOERN GV, BROWN SD: Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J. Infect. (2004) 48:56-65.
41. DOERN GV, HEILMANN KP, HUYNH HK, RHOMBERG PR, COFFMAN SL, BRUEGGEMANN AB: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. (2001) 45:1721-1729.
42. FELMINGHAM D: Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. J. Infect. (2002) 44:3-10.
43. FELMINGHAM D, FARRELL DJ, REINERT R, RENE, MORRISSEY I: Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000). J. Infect. (2004) 48:39-55.
44. SONG JH LEE NY ICHIYAMA S et al.: Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin. Infect. Dis. (1999) 28:1206-1211.
45. BLONDEAU JM: A review of the comparative in vitro activity of 12 antimicrobial agents with a focus on 4 new 'respiratory quinolones'. J. Antimicrob. Chemother. (1999) 43:1-11.
46. DOERN GV: Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin. Infect. Dis. (2001) 33:S187-S192.
47. HOFFKEN G: Epidemiology of respiratory tract infections. European Respiratory Review (2000) 10:149-155.
48. NORRBY R: Linezolid - a review of the first oxazolidinone. Expert Opin. Pharmacother. (2001) 2:293-302.
49. CHEN DK, MCGEER A, DE AZAVED0 J, LOW DE: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. New Engl. J. Med. (1999) 341:233-239.
50. HO PL, YUNG RWH, TSANG DN, QUE TL, HO M, SETO WH: Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicenter study in 2000. J. Antimicrob. Chemother. (2001) 48:659-665.
51. HO PL, QUE TL, TSANG DN, NG TK, CHOW KH, SETO WH: Emergence of fluoroquinolone resistance among multiple resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. (1999) 43:1310-1313.
52. BLONDEAU JM: A review of clinical trials with fluoroquinolones with an emphasis on new agents. Expert Opin. Investig. Drugs (2000) 9:383-413.
53. HEATON VJ, AMBLER J, FISHER LM: Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob. Agents Chemother. (2000) 44:3112-3117.
54. HOOPER DC: Mechanisms of fluoroquinolone resistance. Drug Resistance Updates (1999) 2:38-55.
55. SMITH HJ, NICHOL KA, HOBAN DJ, ZHANEL GG: Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J. Antimicrob. Chemother. (2002) 49:893-895.
56. FISHER LM, GOULD KA, PAN X-S, PATEL S, HEATON VJ: Analysis of dual active fluoroquinolones in Streptococcus pneumoniae. J. Antimicrob. Chemother. (2003) 52:312-316.
57. FISHER LM, HEATON VJ: Dual activity of fluoroquinolones against Streptococcus pneumoniae. J. Antimicrob. Chemother. (2003) 51:463-464.
58. SMITH H, NICHOL KA, HOBAN DJ et al.: Dual activity of fluoroquinolones against Streptococcus pneumoniae: reply. J. Antimicrob. Chemother. (2003) 51:464-465.
59. BLONDEAU JM, ZHAO X, HANSEN G, DRLICA K: Mutant prevention concentration of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2001) 45:433-438.
60. FUKUDA H, KISHII R, TAKEI M et al.: Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target peference and antibacterial activity against Streptococcus pneumonaie. Antimicrob. Agents Chemother. (2001) 45:1649-1653.
61. KISHII R, TAKEI M, FUKUDA H, HAYASHI K, HOSAKA M: Contribution of the 8-methoxy group to the activity of gatifloxacin against Type II topoisomerase of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2003) 47:77-81.
62. PESTOVA E, MILLICHAP JJ, NOSKIN GA et al.: Intracellular targets of moxifloxacin: a comparison with other quinolones. J. Antimicrob. Chemother. (2000) 45:583-590.
63. PAN X, FISHER LM: DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1998) 42:2810-2816.
64. PAN X, FISHER ML: Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. (1997) 41:471-474.
65. FUKUDA H, HIRAMATSU K: Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1999) 43:410-412.
66. GOOTZ TD ZANIEWSKI L HASKELL S et al.: Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topopisomerase IV mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1996) 40:2691-2697.
67. JANOIR C, KELLER V, KITZIS MD, MOREAU NJ, GUTMANN L: High level fluoroquinolone resistance in Streptococcus pneumoniae require mutations in parC and gyrA. Antimicrob. Agents Chemother. (1996) 40:2760-2764.
68. MUNOZ R, DE LA CAMPA AG: ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyraseA subunit in forming resistant phenotype. Antimicrob. Agents Chemother. (1997) 40:2252-2257.
69. PAN X, AMBLER J, MEHTAR S, FISHER LM: Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1996) 40:2321-2326.
70. PAN XS, FISHER LM: Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. (1996) 178:4060-4069.
71. PERICHON B, TANKOVIC J, COURVALIN P: Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1997) 41:1166-1167.
72. TANKOVIC J, PERICHON B, DUVAL J, COURVALIN P: Contribution of mutations in the gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. (1996) 40:2502-2510.
73. ALOVERO FL, PAN X, MORRIS JE, MANZO RH, FISHER LM: Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob. Agents Chemother. (2000) 44:320-325.
74. BINGEN E, LAMBERT-ZECHOVSKY N, MARIANI-KURKDJIAN P, DOIT C, AUJARD Y, FOURNERIE F, MATHIEU H: Bacterial counts in cerebrospinal fluid of children with meningitis. Eur. J. Clin. Microbiol. Infect. Dis. (1990) 9:278-281.
75. FELDMAN W: Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J. Pediatr. (1976) 88:549-552.
76. MITCHISON DA: Drug resistance in mycobacteria. Br. J. Bull. (1984) 50:84-90.
77. FIRSCH AW, TRIPP JT, BARRETT CD Jr, PIDGEON BE: Specific polysaccaride content of pneumoni lungs. J. Exp. Med. (1942) 76:505-510.
78. BLONDEAU JM, HANSEN G, METZLER KL, BORSOS S, CHAU J: Optimal killing of Streptococcus pneumoniae by gemifloxacin, levofloxacin and moxifloxacin. Royal Society of Medicine Press 15-26, (2002).
79. LODE H, FILE TM Jr, MANDELL LA, BALL P, PYPSTRA R, THOMAS M and the 185 GEMIFLOXACIN STUDY GROUP: Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin. Ther. (2002) 24:1915-1936.
80. WILSON R, SCHENTAG JJ, BALL P, MANDELL LA and the 068 STUDY GROUP: A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin. Ther. (2002) 24:639-652.
81. BALL P, FILE TM Jr, TWYNHOLM M, HENKEL T and the 061 STUDY GROUP: Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int. J. Antimicrob. Agents (2001) 18:19-27.
82. FILE TM Jr, SCHLEMMER B, GARAU J, CUPO M, YOUNG C and the 049 CLINICAL STUDY GROUP: Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother. (2001) 48:67-74.
83. LINARES J, DE LA CAMPA AG, PALLARES R: Fluoroquinolone resistance in Streptococcus pneumonaie. New Eng. J. Med. (1999) 341:1546-1547.
84. DRLICA K: Mechanism of fluoroquinolone action. Curr. Opin. Microbiol. (1999) 2:504-508.
85. DAVIES TA, KELLY LM, PANKUCH GA, CREDITO KL, JACOBS MR, APPELBAUM PC: Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob. Agents Chemother. (2000) 44:304-310.
86. TILLOTSON GS, PETERSON LR: Quinolones and pneumococci. J. Antimicrob. Chemother. (2000) 45:709-710.
87. VOUSDEN M, FERGUSON J, RICHARDS JG et al.: Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin. Chemotherapy Basel (1999) 45:512-520.
88. FILE TM Jr, IANNINI PB: A profile of gemifloxacin, a new respiratory fluoroquinolone. Today's Therapeutic Trends (2003) 21:415-435.
89. BLONDEAU JM: Gatifloxacin: a new fluoroquinolone. Expert Opin. Investig. Drugs (2000) 9:1877-1895.
90. BLONDEAU JM, HANSEN G: Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features. Expert Opin. Pharmacother. (2001) 2:317-335.
91. MANDELL LA: Gemifloxacin: survival of the fittest. J. Antimicrob. Chemother. (2000) 46:33-37.
92. KARLOWSKY JA THORNSBERRY C CRITCHLEY IA et al.: Susceptibilities of levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob. Agents Chemother. (2003) 47:1790-1797.
93. THORNSBERRY C, SAHM DF, KELLY LJ et al.: Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clin. Infect. Dis. (2002) 34:S4-S16.
94. LOW DE, DE AZAVEDO J, WEISS K et al.: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. (2002) 46:1295-1301.
95. ZHANEL GG, PALATNICK L, NICHOL KA, BELLYOU T, LOW DE, HOBAN DJ: Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. (2003) 47:1867-1874.
96. ZHANEL GG, PALATNICK L, NICHOL KA, LOW DE, THE CROSS STUDY GROUP, HOBAN DJ: Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. Antimicrob. Agents Chemother. (2003) 47:1875-1881.
97. BLONDEAU JM, VAUGHAN D, LASKOWSKI R, BORSOS S, GROUP TCAS: Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. Int. J. Antimicrob. Agents (2001) 17:457-464.
98. THORNSBERRY C, SAHM DF, KELLY LJ et al.: Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clin. Infect. Dis. (2002) 34:S4-16.
99. OH J-I, PAEK K-S, AHN M-J: In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob. Agents Chemother. (1996) 40:1564-1568.
100. HARDY D, AMSTERDAM D, MANDELL LA, ROTSTEIN C: Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. Antimicrob. Agents Chemother. (2000) 44(3):802-805.
101. MARCHESE A, DEBBIA EA, SCHITO GC: Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project. J. Antimicrob. Chemother. (2000) 46(Suppl. T1):11-15.
102. EDNIE LM, JACOBS MR, APPELBAUM PC: Activity of gemifloxacin, a new broad-spectrum quinolone, against 200 pneumococci by four different susceptibility testing methods. J. Antimicrob. Chemother. (2000) 45(4):525-528.
103. JORGENSEN JH, WEIGEL LM, SWENSON JM, WHITNEY CG, FERRARO MJ, TENOVER FC: Activities of clinafloxacin, gatifloxacin, gemifloxacin and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. (2000) 44:2962-2968.
104. HOBAN DJ, BOUCHILLON SK, KARLOWSKY JA et al.: A comparative in vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group. Antimicrob. Agents Chemother. (2000) 44(11):3008-3011.
105. JONES RN, PFALLER MA, ERWIN ME: Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas. Int. J. Antimicrob. Agents Chemother. (2000) 15:227-230.
106. KOETH LM, JACOBS MR, BAJAKSOUZIAN S, ZILLES A, LIN G, APPELBAUM PC: Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxrella catarrhalis in the United States in 1999-2000. Int. J. Antimicrob. Agents Chemother. (2002) 19:33-37.
107. CORMICAN MG, JONES RN: Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob. Agents Chemother. (1997) 41:204-211.
108. PEREZ-TRALLERO E, GARCIA-REY C, MARTIN-SANCHEZ AM, AGUILAR L, GARCIA-DE-LOMAS J, RUIZ J, Spanish Surveillance Group for Respiratory Pathogens S: Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob. Agents Chemother. (2002) 46:2665-2667.
109. MORTENSEN JE, RODGERS GL: In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis. J. Antimicrob. Chemother. (2000) 45:47-49.
110. NABER KG, HOLLAUER K, KIRCHBAUER D, WITTE W. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections. Int. J. Antimicrob. Agents Chemother. (2000) 16:239-243.
111. ROBLIN PM, REZNIK T, KUTLIN A, HAMMERSCHLAG MR: In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Antimicrob. Agents Chemother. (1999) 43:2806-2807.
112. IEVEN M, GOOSSENS W, DE WIT S, GOOSSENS H: In vitro activity of gemifloxacin compared with other antimicrobial agents against recent clinical isolates of streptococci. J. Antimicrob. Chemother. (2000) 45(Suppl 1):51-53.
113. GERSHON AS, DE AZAVEDO J, MCGEER A et al.: Network. TCBS: Activities of new fluoroquinolones, ketolides and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000. Antimicrob. Agents Chemother. (2002) 46:1553-1556.
114. HEINEMANN B, WISPLINGHOFF H, EDMOND MB, SEIFERT H: Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains. Antimicrob. Agents Chemother. (2000) 44:2211-2213.
115. GOLDSTEIN EJ, CITRON DM, VRENI-MERRIAM C, TYRRELL K, WARREN Y: Activities of gemifloxacin (SB 265805, LB 20304) compared to those of other oral antimicrobial agents against unusual anaerobes. Antimicrob. Agents Chemother. (1999) 43:2726-2730.
116. GOLDSTEIN EJ: Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens. J. Antimicrob. Chemother. (2000) 45(Suppl. 1):55-65.
117. GOLDSTEIN EJC, CITRON DM, WARREN Y, TYRRELL K, VRENI-MERRIAM C: In vitro activity of gemifloxacin (SB 265805) against anaerobes. Antimicrob. Agents Chemother. (1999) 43:2231-2235.
118. MARTINEZ-MARTINEZ L, JOYANES P, SUAREZ AI, PEREA EJ: Activities of gemifloxacin and five other antimicrobial agents against Listeria monocytogenes and Coryneform bacteria isolated from clinical samples. Antimicrob. Agents Chemother. (2001) 45:2390-2392.
119. LEOPHONTE P, FILE JR. TM, FELDMAN C: Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Resp. Med. (In Press).
120. SETHI S, FOGARTY C, FULAMBARKER A: A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Resp. Med. (In Press).